Literature DB >> 34587888

Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review.

Sheng-Xiong Zhang1, Wei Liu2,3, Bo Ai4, Ling-Ling Sun3, Zhe-Sheng Chen5, Li-Zhu Lin3.   

Abstract

BACKGROUND: Surgical resection of the lesion is the standard primary treatment of gastric cancer. Unfortunately, most patients are already in the advanced stage of the disease when they are diagnosed with gastric cancer. Alternative therapies, such as radiation therapy and chemotherapy, can achieve only very limited benefits. The emergence of cancer drug resistance has always been the major obstacle to the cure of tumors. The main goal of modern cancer pharmacology is to determine the underlying mechanism of anticancer drugs.
OBJECTIVES: Here, we mainly review the latest research results related to the mechanism of chemotherapy resistance in gastric cancer, the application of natural products in overcoming the chemotherapy resistance of gastric cancer, and the new strategies currently being developed to treat tumors based on immunotherapy and gene therapy.
CONCLUSION: The emergence of cancer drug resistance is the main obstacle in achieving alleviation and final cure for gastric cancer. Mixed therapies are considered to be a possible way to overcome chemoresistance. Natural products are the main resource for discovering new drugs specific for treating chemoresistance, and further research is needed to clarify the mechanism of natural product activity in patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Gastric cancer; chemoresistance; chemotherapy; multidrug resistance; natural products; overcoming chemoresistance

Mesh:

Substances:

Year:  2022        PMID: 34587888     DOI: 10.2174/1574892816666210929165729

Source DB:  PubMed          Journal:  Recent Pat Anticancer Drug Discov        ISSN: 1574-8928            Impact factor:   4.169


  4 in total

Review 1.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

2.  The lncRNA ZNF667-AS1 Inhibits Propagation, Invasion, and Angiogenesis of Gastric Cancer by Silencing the Expression of N-Cadherin and VEGFA.

Authors:  Chong Yu; Wenqian Chen; Yi Cai; Mingyu Du; Dan Zong; Luxi Qian; Xuesong Jiang; Huanfeng Zhu
Journal:  J Oncol       Date:  2022-07-01       Impact factor: 4.501

3.  Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.

Authors:  Longfei Dai; Xu Wang; Tao Bai; Jianjun Liu; Bo Chen; Wenqi Yang
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

4.  High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.

Authors:  Zhehan Bao; Yanqiang Zhang; Pengcheng Yu; Yi Wang; Can Hu; Yuhang Xia; Li Yuan; Zhiyuan Xu; Xiangdong Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-19       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.